We are live on
!
Find out more
Squarepoint Portfolio holdings
AUM
$85.1B
1-Year Est. Return
20.93%
This Fund
S&P 500
This Quarter
Est. Return
+12.98%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$52.8B
AUM Growth
+$12.4B
(+31%)
Cap. Flow
+$6.6B
Cap. Flow
% of AUM
12.49%
Top 10 Holdings %
Top 10 Hldgs %
10.83%
Holding
4,679
New
953
Increased
1,510
Reduced
1,399
Closed
740
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$763M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$336M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$246M |
| 4 |
Apple
AAPL
|
+$203M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$139M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$158M |
| 2 |
Sherwin-Williams
SHW
|
+$155M |
| 3 |
Goldman Sachs
GS
|
+$139M |
| 4 |
Bank of America
BAC
|
+$127M |
| 5 |
Royal Caribbean
RCL
|
+$126M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.3% |
| 2 | Consumer Discretionary | 7.9% |
| 3 | Healthcare | 4.86% |
| 4 | Financials | 4.75% |
| 5 | Industrials | 3.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3876
Rallybio
RLYB
$86.6M
| $33.5K | ﹤0.01% |
1,755
+480
| +38% | +$11.7K |
|
3877
Shengfeng Development Ltd
SFWL
$57.8M
| $33.4K | ﹤0.01% |
+11,368
| New | +$127K |
|
3878
Polestar Automotive Holding UK
PSNY
$1.98B
| $32.9K | ﹤0.01% |
485
-758
| -61% | -$52.8K |
|
3879
Alto Ingredients
ALTO
$360M
| $32.6K | ﹤0.01% |
+12,249
| New | +$39K |
|
|
LENZ
3880
LENZ Therapeutics
LENZ
$172M
| $32.4K | ﹤0.01% |
+1,767
| New | +$29.2K |
|
3881
Eos Energy Enterprises
EOSE
$1.23B
| $32.1K | ﹤0.01% |
29,447
-95,071
| -76% | -$139K |
|
3882
PharmaCyte Biotech
PMCB
$6.44M
| $32.1K | ﹤0.01% |
+14,846
| New | +$32.2K |
|
|
ADVM
3883
DELISTED
Adverum Biotechnologies
ADVM
| $31.9K | ﹤0.01% |
+4,233
| New | +$38.6K |
|
|
MRSN
3884
DELISTED
Mersana Therapeutics
MRSN
| $31.7K | ﹤0.01% |
+547
| New | +$22K |
|
3885
Alaunos Therapeutics
TCRT
$4.74M
| $31.6K | ﹤0.01% |
+2,975
| New | +$35.8K |
|
|
MKFG
3886
DELISTED
Markforged Holding Corporation
MKFG
| $31.4K | ﹤0.01% |
+3,827
| New | +$33.5K |
|
|
EVA
3887
DELISTED
Enviva Inc.
EVA
| $31.2K | ﹤0.01% |
+31,292
| New | +$86.9K |
|
3888
Broadwind
BWEN
$113M
| $29.3K | ﹤0.01% |
10,593
-2,593
| -20% | -$6.85K |
|
3889
Bionano Genomics
BNGO
$12.7M
| $28.8K | ﹤0.01% |
+254
| New | +$26.5K |
|
|
TVRD
3890
Tvardi Therapeutics
TVRD
$23.5M
| $28.7K | ﹤0.01% |
+1,072
| New | +$44.4K |
|
3891
Traeger
COOK
$170M
| $28.5K | ﹤0.01% |
+209
| New | +$27K |
|
3892
FTC Solar
FTCI
$47.4M
| $28.5K | ﹤0.01% |
+4,119
| New | +$37.4K |
|
3893
Kopin
KOPN
$663M
| $28.5K | ﹤0.01% |
14,020
-3,551
| -20% | -$5.07K |
|
|
NNDM
3894
Nano Dimension
NNDM
$309M
| $27.5K | ﹤0.01% |
+11,468
| New | +$28.8K |
|
3895
Chanson International
CHSN
$2.76M
| $27.2K | ﹤0.01% |
+3
| New | +$76.4K |
|
3896
Genprex
GNPX
$3.94M
| $27.1K | ﹤0.01% |
+3
| New | +$34.6K |
|
|
CKPT
3897
DELISTED
Checkpoint Therapeutics
CKPT
| $27K | ﹤0.01% |
+11,812
| New | +$25.7K |
|
3898
Ginkgo Bioworks
DNA
$481M
| $25.7K | ﹤0.01% |
+380
| New | +$23.3K |
|
|
FABC
3899
Fabric.AI Inc
FABC
$16.8M
| $25.2K | ﹤0.01% |
+894
| New | +$27.1K |
|
3900
Zedge
ZDGE
$38.9M
| $25.1K | ﹤0.01% |
+10,701
| New | +$21.5K |
|
Similar funds
Squarepoint's Q4 2023 Portfolio in Review
As of Q4 2023, Squarepoint held 4,679 positions worth $52.8B, up 31% from $40.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Squarepoint deployed $6.6B of net new capital in Q4 2023, opening 953 new positions and adding to 1,510 existing holdings. Its largest new stake was iShares Core S&P 500 ETF: 550,000 shares worth $263M.
By sector, the portfolio is most concentrated in Technology at 9.3% of assets, down from 11% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Intuit, an estimated $158M trimmed.
- Squarepoint's largest Q4 2023 buy was iShares Core S&P 500 ETF: 550,000 shares worth $263M.
- Squarepoint added most to State Street SPDR S&P 500 ETF Trust in Q4 2023, an estimated $763M increase.
- Squarepoint's biggest Q4 2023 reduction was Intuit, cutting an estimated $158M.
- Squarepoint fully exited State Street SPDR S&P MIDCAP 400 ETF Trust in Q4 2023, selling an estimated $97.9M.
- Squarepoint's ten largest holdings make up 11% of its $52.8B portfolio in Q4 2023.
- Squarepoint opened 953 new positions and closed 740 in Q4 2023.
- Squarepoint's portfolio value rose 31% quarter-over-quarter to $52.8B.
Based on Squarepoint's 13F filing for Q4 2023, filed 14 Feb 2024.